SEC Comment Letter 0000000000-24-004723 to Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc.
Date: April 29, 2024 · CIK: 0001585608 · Accession: 0000000000-24-004723
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278861
Letter
United States securities and exchange commission logo April 29, 2024 Lisa Conte Chief Executive Officer and President Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Re:Jaguar Health, Inc. Registration Statement on Form S-3 Filed April 22, 2024 File No. 333-278861 Dear Lisa Conte: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Lee, Esq.
Show Raw Text
United States securities and exchange commission logo
April 29, 2024
Lisa Conte
Chief Executive Officer and President
Jaguar Health, Inc.
200 Pine Street, Suite 400
San Francisco, CA 94104
Re:Jaguar Health, Inc.
Registration Statement on Form S-3
Filed April 22, 2024
File No. 333-278861
Dear Lisa Conte:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Lee, Esq.